{"filing":{"accession_number":"0001213900-26-112266","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-10-26","report_date":"2026-10-26","primary_document":"ea0309623-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026112266/ea0309623-6k_canfite.htm"},"events":[{"id":37791,"run_id":34830,"accession_number":"0001213900-26-112266","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces final positive Phase IIa clinical trial data for namodenoson in pancreatic cancer presented at ESMO 2026, including achievement of the primary safety endpoint and exploratory survival findings. While the disclosure concerns clinical development progress—a material operational milestone for a biotech company—it does not fit the specific event types of earnings_release, ma_activity, material_litigation, or other named categories. The data presentation represents a significant clinical advancement that would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting classification as operational_other.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-10-26","form":"6-K","submitted_at":null,"items":[{"id":42625,"accession_number":"0001213900-26-112266","item_number":"EX-99.1","item_title":"ea030962301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces final positive Phase IIa clinical trial data for namodenoson in pancreatic cancer presented at ESMO 2026, including achievement of the primary safety endpoint and exploratory survival findings. While the disclosure concerns clinical development progress—a material operational milestone for a biotech company—it does not fit the specific event types of earnings_release, ma_activity, material_litigation, or other named categories. The data presentation represents a significant clinical advancement that would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting classification as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T11:04:38.090030+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42625,"accession_number":"0001213900-26-112266","item_number":"EX-99.1","item_title":"ea030962301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces final positive Phase IIa clinical trial data for namodenoson in pancreatic cancer presented at ESMO 2026, including achievement of the primary safety endpoint and exploratory survival findings. While the disclosure concerns clinical development progress—a material operational milestone for a biotech company—it does not fit the specific event types of earnings_release, ma_activity, material_litigation, or other named categories. The data presentation represents a significant clinical advancement that would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting classification as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T11:04:38.090030+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-10-26"}]}
